Full Press Release Details
IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025
New York, NY April 28, 2025 IN8bio, Inc. (Nasdaq:
INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta ( ) T cell therapies for cancer and autoimmune diseases, today announced
new preclinical data from its innovative T cell engager ( -TCE)
platform. The data will be presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting on April 30, 2025. The data showed that IN8bio s new -TCE platform demonstrated potent and consistent cancer-killing activity across targets in leukemia models, while avoiding the secretion of cytokines that drive the dangerous side effects seen with other TCE
based immune therapies.
Unlike traditional TCEs that rely on CD3 to activate all T cells in the body often triggering excessive inflammatory
responses, potential T cell exhaustion and other serious side effects IN8bio s next-gen platform is designed to specifically activate only T cells, a small but powerful subset of immune cells. These cells can naturally detect, phagocytose (eat) and kill tumors cells without needing to be trained to recognize specific targets. The
platform s lead molecules, INB-619 (targeting CD19) and INB-633 (targeting CD33), were able to eliminate cancer cells in preclinical studies with minimal release of
inflammatory cytokines. This potentially offers a lower risk of cytokine release syndrome (CRS) or the neurotoxicity that can impact 60-75% of patients treated with conventional CD3 TCEs.
William Ho, CEO and co-founder of IN8bio, commented, Our INB-600 TCE platform combines the natural tumor-fighting abilities of T cells with bispecific engagers to generate a more
precise and powerful way to mobilize the immune system against cancer cells. These early results in leukemia models are exciting, and we believe this technology can eventually be applied to other hard-to-treat cancers, and even certain autoimmune diseases.
Key highlights from the in vitro
Because this new off-the-shelf platform can drive T cell expansion without the need for genetic engineering, it has the potential to offer a more scalable and flexible approach to building next-generation
IN8bio continues to expand its T cell
therapeutic pipeline beyond genetically engineered and drug-resistant cellular therapies and is exploring various disease indications and any opportunities for partnership with the INB-600 platform. This
preclinical data reinforces the company s differentiated strategy to build modular and scalable therapeutic approaches to leverage the power of T cells
to target malignancies with increased precision and reduced toxicity.
The AACR 2025 poster is available on the investor section of the company s
website at https://investors.in8bio.com.
IN8bio is a clinical-stage biopharmaceutical company developing T
cell-based immunotherapies for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to
differentiate between healthy and diseased tissue. The company s lead program, INB-100, is focused on acute myeloid leukemia evaluating haplo-matched
allogeneic T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI T cells, in combination with standard of care, for glioblastoma, and advancing novel
T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit www.IN8bio.com.
Forward-Looking Statements
This press release may
contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as aims, anticipates,
believes, could, estimates, expects, forecasts, goal, intends, may, plans, possible, potential, seeks,
will and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release
include, but are not limited to, statements regarding: the ability of the INB-600 platform to offer a scalable, flexible, more precise and more powerful alternative to conventional CD3-based approaches and have applications in autoimmune diseases as well as cancer; IN8bio s plans to expand its pipeline beyond genetically engineered and drug-resistant cellular therapy and explore various
disease indications and any opportunities for partnership with the INB-600 platform; and other statements that are not historical fact. IN8bio may not actually achieve the plans, intentions or expectations
disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these
forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as IN8bio s ability to meet
anticipated deadlines and milestones; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio s product candidates; the risk that IN8bio may be unable to raise
additional capital and could be forced to delay, further reduce or to explore other strategic options for certain of its development programs, or even terminate its operations; IN8bio s ability to continue to operate as a going concern; the
risk that IN8bio may not realize the intended benefits of its -TCE platform or DeltEx platform; the availability and timing of results from preclinical
studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of
future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio s product candidates; the uncertainty of regulatory approvals to conduct
trials or to market products; IN8bio s reliance on third
parties, including licensors and clinical research organizations; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking
statements, which are described in greater detail in the section entitled Risk Factors in IN8bio s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on
March 13, 2025, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any
forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.